If you have been reading about MOD GRF 1-29 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
== Producers == As of October 2019, there were two producers of iodine-125, the McMaster Nuclear Reactor in Hamilton, Ontario, Canada; and a VVR-SM research reactor in Uzbekistan. The McMaster reactor is presently the largest producer of iodine-125, producing approximately 60 per cent of the global supply in 2018; with the remaining global supply produced at the reactor based in Uzbekistan. Annually, the McMaster reactor produces enough iodine-125 to treat approximately 70,000 patients. In November 2019, the research reactor in Uzbekistan shut down temporarily in order to facilitate repairs. The temporary shutdown threatened the global supply of the radioisotope by leaving the McMaster reactor as the sole producer of iodine-125 during the period. Prior to 2018, the National Research Universal (NRU) reactor at Chalk River Laboratories in Deep River, Ontario, was one of three reactors to produce iodine-125. However, on March 31, 2018, the NRU reactor was permanently shut down ahead of its scheduled decommissioning in 2028, as a result of a government order. The Russian nuclear reactor equipped to produce iodine-125, was offline as of December 2019.
== Legality == The legality of AI-generated pornography remains an evolving issue. In some countries, laws concerning digital simulation may apply indirectly, particularly when the generated content features images of real people without their consent. Additionally, most existing laws regulate deepfake pornography of nonconsenting individuals, rather than fully synthesized AI pornography.
==== Pilosan research ==== Casali et al. (2026) identify a poorly developed dental alveolus in a specimen of Nothrotherium maquinense from the Pleistocene strata from Brazil, occupying the position of caniniform alveolus in Neogene nothrotheriids, and interpreted as a possible case of partial re-expression of a lost ancestral dental condition in the studied individual. Revision of nematheriine scelidotheriid sloths from the Miocene Santa Cruz Formation (Argentina) is published by Boscaini et al. (2026), who assign all studied fossils to the genus Nematherium, with the majority of them assigned to the species N. angulatum New fossil material of Ocnotherium giganteum, including a nearly complete skull and two partial skeletons, is described from the Pleistocene strata from Brazil by Pujos et al. (2026), who recover O. giganteum as a mylodontine mylodontid. Evidence from the study of a mylodontid coprolite from the Pleistocene strata from the Cueva Cacao 1.A site (Argentina) indicative of a grazing-browsing dietary niche of the producer is presented by Velázquez et al. (2026). Zicos et al. (2026) compare the utility of three ancient DNA extraction methods for recovery of DNA from coprolites of Mylodon darwinii and soil samples from Cueva del Milodón (Chile), and report recovery of both sloth mitochondrial genomes and signatures of local flora. Harper et al.
Sources: en.wikipedia.org
=== Radioactive contamination === RTGs pose a risk of radioactive contamination: if the container holding the fuel leaks, the radioactive material may contaminate the environment. For spacecraft, the main concern is that if an accident were to occur during launch or a subsequent passage of a spacecraft close to Earth, harmful material could be released into the atmosphere; therefore their use in spacecraft and elsewhere has attracted controversy. However, this event is not considered likely with current RTG cask designs. For instance, the environmental impact study for the Cassini–Huygens probe launched in 1997 estimated the probability of contamination accidents at various stages in the mission. The probability of an accident occurring which caused radioactive release from one or more of its three RTGs (or from its 129 radioisotope heater units) during the first 3.5 minutes following launch was estimated at 1 in 1,400; the chances of a release later in the ascent into orbit were 1 in 476; after that the likelihood of an accidental release fell off sharply to less than 1 in a million. If an accident which had the potential to cause contamination occurred during the launch phases (such as the spacecraft failing to reach orbit), the probability of contamination actually being caused by the RTGs was estimated at 1 in 10. The launch was successful and Cassini–Huygens reached Saturn. To minimize the risk of the radioactive material being released, the fuel is stored in individual modular units with their own heat shielding.
Conversely, with some other catalysts, ethylene oxide may be reduced by hydrogen to ethylene with the yield up to 70%. The reduction catalysts include mixtures of zinc dust and acetic acid, of lithium aluminium hydride with titanium trichloride (the reducing agent is actually titanium dichloride, formed by the reaction between LiAlH4 and TiCl3) and of iron(III) chloride with butyllithium in tetrahydrofuran.
John Kampfner, author, broadcaster and commentator; executive director at Chatham House; has written and presented for Reuters, The Daily Telegraph; chief political correspondent at the Financial Times; political commentator for BBC's Today radio programme; political correspondent on Newsnight; was chair of the Clore Duffield Foundation, Council of King's College London; Chief Executive of the freedom of expression organisation Index on Censorship and established Creative Industries Federation; shortlisted for the Orwell Book prize. Efraim Karsh (born 6 September 1953) British-Israeli historian at King's College London; director of political studies Bar-Ilan University the Begin-Sadat Center for Strategic Studies).; former director of Middle East Forum; held posts at Harvard, Columbia universities, Sorbonne, London School of Economics, Helsinki University, International Institute for Strategic Studies, Kennan Institute for Advanced Russian Studies in Washington D.C., and Jaffee Center for Strategic Studies at Tel Aviv University; in 1989 joined King's College London; has contributed articles to The New York Times, The Los Angeles Times, The Wall Street Journal, The Times (London) and The Daily Telegraph. His book Palestine Betrayed argued that 1948 Palestinian expulsion and flight was "exclusively of their own making".
=== Hemolytic transfusion reaction === There are many different varieties of abnormal reactions to blood transfusion. Among these, a potentially life-threatening reaction is known as a hemolytic transfusion reaction. This is an immune mediated reaction where recipient antibodies attack donor red blood cell antigen(s), causing hemolysis of donor cells. The reaction may occur during, immediately after, or up to 28 days later. An acute reaction is observed within the first 24 hours, whereas a delayed reaction will be observed between 24 hours and 28 days after transfusion.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.